Treatment of recurrent vulvo-vaginal candidiasis with sustained-released butoconazole pessary.
- Author:
Ling Zhi HENG
1
;
Yujia CHEN
;
Thiam Chye TAN
Author Information
1. Department of Obstetrics and Gynaecology, KK Women's and Children's Hospital, Singapore. drtctan@me.com
- Publication Type:Case Reports
- MeSH:
Adult;
Antifungal Agents;
administration & dosage;
Candidiasis, Vulvovaginal;
drug therapy;
Female;
Humans;
Imidazoles;
administration & dosage;
Middle Aged;
Pessaries;
Recurrence
- From:Singapore medical journal
2012;53(12):e269-71
- CountrySingapore
- Language:English
-
Abstract:
Vulvo-vaginal candidiasis (VVC) is a common infection among women. 5% of women with acute infection experience recurrent vulvo-vaginal candidiasis (RVVC). There is currently no optimal or recommended regime for RVVC. Although antifungal agents, such as imidazoles, have been successfully used as a first-line treatment for acute VVC, its effectiveness is limited in RVVC. This could be due to patient factors, drug application (such as leakage) or dosing factors. A sustained-release (SR) bioadhesive vaginal cream (2% butoconazole nitrate) has incorporated VagiSite technology, a topical drug delivery system that allows SR of the drug. We describe its efficacy and the successful use of a butoconazole-SR formulation in the treatment of two cases of RVVC.
